GlaxoSmithKline

News GlaxoSmithKline

• New hope in fight against multi-resistant germs

  An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can on more

• GlaxoSmithKline wins top prize at IChemE Awards

  GlaxoSmithKline clinched the top prize at the IChemE 2012 Awards in recognition of its radical change in the manufacture of pharmaceuticals. The organisation won the Outstanding Achievement in Chemical Engineering Award alongside project partners GEA, Siemens, Sagentia and the Universities of Newcas more

• Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis

  Janssen Biologics announced it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK).  Sirukumab is a human anti-interleukin (IL)-6 monoclonal antibody being studied for the treatment of adults with moderately to severely act more

White papers GlaxoSmithKline

• Orphan Drugs – An Alternative to the declining Blockbuster Model?
  

  Up until the new millennium, the pharmaceutical industry grew stronger by 11%. However, the blockbuster model is increasingly at risk and the declining growth rates in the industry require a search for new strategies. In this context, orphan drugs are becoming increasingly important more

Publications GlaxoSmithKline

• Treatment Success in Cancer: Industry Compared to Publicly Sponsored Randomized Controlled Trials

  by Benjamin Djulbegovic, Ambuj Kumar, Branko Miladinovic, Tea Reljic, Sanja Galeb, Asmita Mhaskar, Rahul Mhaskar, Iztok Hozo, Dongsheng Tu, Heather A. Stanton, Christopher M. Booth, Ralph M. Meyer Objective To assess if commercially sponsored trials are associated with higher success rates than p more

• Abstracts of the 21st International Isotope Society (UK group) symposium: synthesis and applications of labelled compounds 2012

  Meeting Summary The 21st annual symposium of the International Isotope Society's United Kingdom Group took place at the Møller Centre, Churchill College, Cambridge, UK, on Friday 12th October 2012. The meeting was attended by around 60 delegates from academia and industry, the life sciences, che more

• Toward clinical transparency

  Nature Medicine 18, 1593 (2012). doi:10.1038/nm.3000 Big pharma has historically made some substantial missteps regarding the full reporting of clinical trial results, but a new initiative by GlaxoSmithKline is a move in the right direction. more

Market studies GlaxoSmithKline

• Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report provides comp more

• Healthcare, Regulatory and Reimbursement Landscape - US

  Introduction Industry analysis specialist GlobalData, has released its new report, “Healthcare, Regulatory and Reimbursement Landscape - US”. The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of the US. It identifies the key t more

• Rare and Niche Diseases Catalyst Monitor - Key Event Analysis H1 2012

  Introduction GlobalData’s new report, "Rare and Niche Diseases Catalyst Monitor - Key Event Analysis H1 2012" takes a look at rare and niche diseases, which are an area of intense interest in the global biopharmaceutical industry today. The passage of the Orphan Drug Act in the United States in 19 more

Websites GlaxoSmithKline